instruction:
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
question:
Following Italy in extending the lockdown but announcing no immediate easing of restrictive measures as in Spain, Macron said the tense situation in hospitals in Paris and eastern France meant there could be no let-up in the country. Since March 17, France’s 67 million people have been ordered to stay at home except to buy food, go to work, seek medical care or get some exercise on their own. The lockdown was originally scheduled to end on Tuesday. “I fully understand the effort I’m asking from you,” Macron told the nation in a televised address at the end of the lockdown’s fourth week, adding the current rules were working. “When will we be able to return to a normal life? I would love to be able to answer you. But to be frank, I have to humbly tell you we don’t have definitive answers,” he said. Schools and shops would progressively reopen on May 11, Macron said. But restaurants, hotels, cafes and cinemas would have to remain shut longer, he added. International arrivals from non-European countries will remain prohibited until further notice. Macron, whose government has faced criticism over a shortage of face masks and testing kits, said that by May 11, France would be able to test anyone presenting COVID-19 symptoms and give nonprofessional face masks to the public. Macron also said he had asked his government to present this week new financial aid for families and students in need. Acknowledging his country had not been sufficiently prepared early on to face the challenges posed by the outbreak of the new coronavirus, Macron appeared to seek a humble tone in contrast to the war-like rhetoric of his previous speeches. “Were we prepared for this crisis? On the face of it, not enough. But we coped,” he said. “This moment, let’s be honest, has revealed cracks, shortages. Like every country in the world, we have lacked gloves, hand gel, we haven’t been able to give out as many masks as we wanted to our health professionals.”  The French, long accustomed to being told their high taxes paid for the “best healthcare in the world,” have been dismayed by the rationing of critical drugs, face masks and equipment and have watched with envy the situation in neighbouring Germany. Macron’s acknowledgment of the shortcomings was broadly well-received. “It’s not every day you hear a president offer a mea culpa and dare say ‘we have no definitive answers.’ Reassuring and necessary sincerity,” analyst Maxime Sbaihi of the think tank GenerationLibre said. After a relentless increase until the first week of April, the number of patients in French hospitals’ intensive care units has started to decline, prompting health authorities to call a plateau in the epidemic. But if French hospitals are just about coping, helped by a massive effort to transfer patients by plane, helicopter or even high-speed train from hospitals in the east and Paris to the west, nursing homes have been overwhelmed. By Monday, the coronavirus had claimed 14,967 lives in France, the fourth-highest death toll in the world, with more than 98,076 confirmed cases, according to official figures. “We’ll have better days, and we’ll return to happy days,” Macron said.
answer:
Promising 'better days,' Macron extends France's lockdown until May 11.


question:
Although there was no discussion of costs, the article was clear in stating that vaccines are for the most part in an early stage of development, so this omission is understandable. We wanted to see better coverage of the data here. The story leads with an anecdote about a patient who kicked a pack-a-day smoking habit after treatment with a nicotine vaccine in a study. And later, the story says that smokers who received that vaccine were “about three times as likely to be off cigarettes 44 weeks after vaccination than subjects given a placebo.” The story should have provided the absolute rates of success reported in the study, which were only 16% for the treatment group compared with 6% for the placebo group, according to theheart.org. Elsewhere, the story describes an experimental anticocaine vaccine that was apparently very effective in a mouse study; it could have reported on phase II human data that is available for the TA-CD anticocaine vaccine that was also mentioned in the story. These data again suggest that only a minority of patients may benefit from the use of anti-addiction vaccines. The story states that “clinical trials have so far revealed no significant side effects” from vaccine treatments. However, we think the story should have included an important caveat: that these are early stage trials involving small numbers of patients that can’t provide conclusive evidence of safety. In addition, it should be recognized that addictions are chronic conditions and these vaccine treatments are likely to be long-term as well. Therefore, longer-term adverse effects should be expected, especially for a treatment that interferes with molecules closely related to the body’s natural chemical messengers. The story could have been a bit more circumspect on this point. The promise of this new vaccine technology is counterbalanced by coverage of the uncertainties. The story gives appropriate weight to the disappointing results reported in a number of early clinical studies, noting: “Failures have so far outnumbered successes.” The story adds that even in one of the successful vaccine studies, the benefits were not as robust as those seen with a smoking cessation drug that is already on the market. There also is no prospect for a vaccine to treat alcoholism, according to the story. The article should have been more direct about the limitations of mouse research, and there was not enough detail on the data published in the various studies reported on (a deficiency we address under the “Benefits” criterion). However, since the story was trying to present a broad overview of happenings in the field and wasn’t attempting to summarize any particular study, we’ll give the benefit of the doubt here and award a satisfactory. The story didn’t exaggerate the effects of substance abuse disorders or otherwise engage in disease-mongering. The sourcing of this story was good. We hear from academics, government researchers, and industry executives. Their voices provide balance and give texture to the coverage. It should be noted, however, that most of these experts have a vested interest in the field or the success of a particular treatment, whether because of industry ties or because they are leading experiments on a particular approach. Even the government experts might be biased by their provision of significant financial support for research in this area. It would have been nice to hear a comment about the vaccines from someone who is certifiably free of all potential conflicts. But we can’t justify docking points since there is no voice that is overly enthusiastic about the concept. The story compares the potential of vaccines with the benefits of existing medications for addiction–and notes that the available drugs might work better. We would like to have seen more ink given to the role of behavioral approaches in the management of addiction, which are supported by considerable evidence. However, the story does acknowledge that vaccines “would likely be used alongside psychological therapy.” We’ll call it good enough for a satisfactory. The article helpfully states that “It could be years, if ever, before any vaccines to treat addiction reach the market.” The article does a good job of describing how far along the various experimental vaccines mentioned in the article are in their development. Although the story could have provided more background on the history of anti-addiction vaccines (a heroin vaccine was explored in the 1970s), the treatments being explored now are different from anything currently available. So we don’t think this story overstates the novelty of the research. This story is not based on a news release.
answer:
Quest for Vaccines to Treat Addiction


question:
Texas health officials have been offering the vaccinations since Monday, three days after lawmakers were notified that a page had come down with the highly infectious disease. At least two House members and their staffs received vaccinations, and one representative who often takes her 9-month-old to work called her pediatrician to check what precautions she should take. The whooping cough case is being held up as a warning in the Texas House, where politically active vaccination opponents have tried to claim territory. “I know it’s on people’s minds,” said state Rep. Gene Wu, a Democrat from Houston. “People speculate about which members are going to come down with it because they didn’t get vaccinated.” Vaccinations are a recurring fight in statehouses, including in Washington state, where a measles outbreak has lawmakers trying to limit vaccine exemptions. A bill in New York would let minors get vaccinated without parental consent, while a California proposal would give state health officials — instead of local doctors — the power to decide which children can skip vaccinations before attending school. Whooping cough is a bacterial infection also known as pertussis that often starts with what feels like a mild cold, followed by weeks of intense coughing fits. The disease gets its name from the sound some people make at the end of a coughing jag when they gasp for breath. There are about 10,000 to 40,000 cases of pertussis reported each year, according to the federal Centers for Disease Control. Forty-seven people in the Texas Capitol received pertussis vaccinations supplied by state health officials Monday and Tuesday, said Lara Anton, a spokeswoman with the Texas Department of State Health Services. She said she could not disclose any details about the person who contracted whooping cough, citing privacy, but House pages are typically children around middle-school age. “It was a large number of people who were potentially exposed,” Anton said. In Texas, the number of schoolchildren claiming vaccine exemptions has surged from about 2,300 students in 2003 to more than 56,000. Some legislation filed this year would make it easier to opt out of vaccines or prevent state health officials from tracking exemption data. On Wednesday, worries over vaccination exemptions in Texas could even creep into a vote over a new $250 billion state budget. A Democrat filed one amendment that would study vaccination levels at child-care facilities. “That a case of pertussis was confirmed on the House floor should be a wake-up call,” said Rekha Lakshmanan, director of advocacy and public policy for The Immunization Partnership, based in Houston. “The fact it happened inside lawmakers’ own house should give everyone a reality check.” ___ Follow Paul J. Weber on Twitter: https://twitter.com/pauljweber
answer:

Whooping cough case at Texas Capitol leads to vaccinations.